CapitalStars Financial Research Pvt Ltd


CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market.we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors.we provide intraday as well as delivery stock tips in NSE and BSEand commodity tips in MCX and NCDEX. Read More

Commodity Market Services

Commodity Market Services

In this service we provide 3-4 intraday calls in MCX with a high level of accuracy. The calls are given in Precious Metals, Base Metals and Energies. You can also avail Free Tips for two days to test our accuracy and if satisfied you can join the services with Capital Stars. Read More

Nifty Market Services

Nifty Future Services

We provide you around 1-2 nifty calls, Bank Nifty Futures, nifty futures tips, sgx nifty tips Daily. You can gain more profit, Get 2 days free trial calls. Read More

Equity Market Services

Equity Market Services

In this service we provide 2-4 intraday stock cash calls in NSE/BSE with a high level of accuracy.You can also avail Free Stock Tips for two days to test our accuracy and if satisfied you can join stock cash services with Capital Stars. Read More

Register now

CapitalStars provides Free Trial in Intraday as well as in Positional Services of Equity, Derivatives, and Commodities and Forex Markets. We provide recommendations in NSE, BSE, MCX, NCDEX, and MCX-SX etc. We render you enough entry and exit time in our calls so clients can easily maximize their profits. Read More

Monday, 24 April 2017

Divis Labs hits 52-week low : 24 Apr 2017

Divi’s Laboratories hit 52-week low of Rs 607, down 4% on BSE in early morning trade after the company on Saturday said that the US drug regulator has issued a warning letter for its unit-II at Visakhapatnam, Andhra Pradesh.

“The US Food and Drug Administration (USFDA) have issued a Warning Letter for the company's Unit-II at Visakhapatnam,” Divis Laboratories said in a BSE filing.

The company responded to the US-FDA inspection observations with an appropriate remediation process to overcome the deficiencies observed, it added.

The company said, in the import alert issued, US-FDA has exempted several products manufactured at the company's Unit-II at Visakhapatnam, Andhra Pradesh. It will continue to supply these active ingredients to meet its obligations to the customers.

“Divi's Labs, along with external consultants and subject matter experts, are working to address the concerns of the US-FDA and is making all efforts to fully meet the compliance requirements. We will respond to this Warning Letter with a detailed plan within the stipulated time,” it added.

The US FDA had earlier had issued form 483 with five observations after inspecting the Visakhapatnam unit between November 29, 2016 and December 6, 2016.

In past six months, the stock has underperformed the market by falling 52% as compared to 4% rise in the S&P BSE Sensex.

At 9:21 am; the stock was down 1.7% at Rs 620 on BSE as compared to 0.34% rise in the benchmark index.  A combined 734,175 equity shares changed hands on the counter on BSE and NSE so far.

Looking for investment in Share Market, CapitalStars Financial Research Private Limited provides you best investments Tips in Share Market.It  daily provides intraday and Future calls.We generate intraday as well as delivery calls in Stock cash and F&O in NSE & BSE, Commodities.

Get more details here:-

Commodity Market Tips
Equity Tips
Share Market Tips

* Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
* CapitalStars Investment Adviser: SEBI Registration Number: INA000001647


Post a Comment